While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in
proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent …

We report small molecular PROTAC compounds targeting the androgen receptor N-terminal
domain (AR-NTD), which were obtained by tethering AR-NTD antagonists and different …

The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important
role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker …

Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading
cause of cancer-related death for American men due to a subset of patients progressing to …

With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa,
particularly the advanced and metastatic disease, has been the focus of a number of studies …

The androgen receptor is a transcription factor and validated therapeutic target for prostate
cancer. Androgen deprivation therapy remains the gold standard treatment, but it is not …

Prostate cancer (PCa) is the second most common cause of cancer‐related mortality in men
in the United States. The androgen receptor (AR) and the physiological pathways it …

The androgen receptor (AR) is dominant in prostate cancer (PCa) pathology. Current
therapeutic agents for advanced PCa include androgen synthesis inhibitors and AR …

Background: With prostate cancer being the fifth-greatest cause of cancer mortality in 2020,
there is a dire need to expand the available treatment options. Castration-resistant prostate …